EUVIMEDEUVIMED entdecken
Leitlinie

Recommendations for testing of predictive marker HER2 in patients with invasive breast cancer. Recommendations in accordance with American Society of Clinical Oncology (ASCO) guidelines from 30th May 2018

Andrzej Marszałek, Maciej Krzakowski

Oncology in Clinical Practice · 25.11.2018 · 14 (5) · 272-277

DOI: 10.5603/ocp.2018.0034 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Oncology in Clinical Practice, online erschienen am 25.11.2018. Verfasst von Andrzej Marszałek und 1 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Marszałek, A., & Krzakowski, M. (2018). Recommendations for testing of predictive marker HER2 in patients with invasive breast cancer. Recommendations in accordance with American Society of Clinical Oncology (ASCO) guidelines from 30th May 2018. Oncology in Clinical Practice, 14(5), 272-277. https://doi.org/10.5603/ocp.2018.0034

Vancouver

Marszałek A, Krzakowski M. Recommendations for testing of predictive marker HER2 in patients with invasive breast cancer. Recommendations in accordance with American Society of Clinical Oncology (ASCO) guidelines from 30th May 2018. Oncology in Clinical Practice. 2018;14(5):272-277. doi:10.5603/ocp.2018.0034

BibTeX
@article{Marszaek2018,
  author = {Marszałek, Andrzej and Krzakowski, Maciej},
  title = {Recommendations for testing of predictive marker HER2 in patients with invasive breast cancer. Recommendations in accordance with American Society of Clinical Oncology (ASCO) guidelines from 30th May 2018},
  journal = {Oncology in Clinical Practice},
  year = {2018},
  volume = {14},
  number = {5},
  pages = {272--277},
  doi = {10.5603/ocp.2018.0034}
}
Kostenlos starten →